Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2011
Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castro Mario, Rubin Adalberto, Laviolette Michel, Hanania Nicola A, Armstrong Brian, Cox Gerard, AIR2 Trial Study Group
Аннотация
BACKGROUND: Bronchial thermoplasty (BT) has been demonstrated to be safe and effective in the treatment of severe persistent asthma out to at least 1 year. Preclinical studies have demonstrated that the reduction in airway smooth muscle after bronchial thermoplasty persists out to at least 3 years.
OBJECTIVES: To examine the persistence of effectiveness of BT 2 years posttreatment in subjects with severe asthma.
METHODS: Subjects participating in the long-term safety follow-up phase of the Asthma Intervention Research 2 (AIR2) Trial were evaluated by comparing the proportion of subjects who experienced exacerbations, adverse events, or healthcare utilization during the first year (year 1) after BT treatment with the proportion of subjects who experienced the same during the subsequent 12 months (year 2).
RESULTS: Severe exacerbations, respiratory adverse events, emergency department visits for respiratory symptoms, and hospitalizations for respiratory symptoms (proportion of subjects experiencing and rates of events), and stability of pre- and post-bronchodilator forced expiratory volume in 1 second (FEV(1)), were comparable between years 1 and 2. The proportion of subjects experiencing severe exacerbations in year 2 after BT was 23.0%, compared with 30.9% in year 1.
CONCLUSIONS: The reduction in the proportion of subjects experiencing severe exacerbations after BT is maintained for at least 2 years. Bronchial thermoplasty provides beneficial long-term effects on asthma outcomes in patients with severe asthma.
TRIAL REGISTRATION: clinicaltrials.gov, Identifier: NCT00231114.
OBJECTIVES: To examine the persistence of effectiveness of BT 2 years posttreatment in subjects with severe asthma.
METHODS: Subjects participating in the long-term safety follow-up phase of the Asthma Intervention Research 2 (AIR2) Trial were evaluated by comparing the proportion of subjects who experienced exacerbations, adverse events, or healthcare utilization during the first year (year 1) after BT treatment with the proportion of subjects who experienced the same during the subsequent 12 months (year 2).
RESULTS: Severe exacerbations, respiratory adverse events, emergency department visits for respiratory symptoms, and hospitalizations for respiratory symptoms (proportion of subjects experiencing and rates of events), and stability of pre- and post-bronchodilator forced expiratory volume in 1 second (FEV(1)), were comparable between years 1 and 2. The proportion of subjects experiencing severe exacerbations in year 2 after BT was 23.0%, compared with 30.9% in year 1.
CONCLUSIONS: The reduction in the proportion of subjects experiencing severe exacerbations after BT is maintained for at least 2 years. Bronchial thermoplasty provides beneficial long-term effects on asthma outcomes in patients with severe asthma.
TRIAL REGISTRATION: clinicaltrials.gov, Identifier: NCT00231114.
Предметные рубрики MeSH
AdolescentAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAdultAgedAnti-Asthmatic AgentsAsthmaBronchiBronchoscopyCatheter AblationChronic DiseaseDisease ProgressionHospitalizationHumansMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRespiratory Function TestsSeverity of Illness IndexTreatment OutcomeYoung Adult